Samsung Biologics announces 3 trillion won rights offering for expansion

Samsung Biologics, a leading contract development and manufacturing organization (CDMO), announced on August 28, 2026, its intent to raise KRW 3 trillion through a rights offering. The funds will be used to fuel the company's three-dimensional growth strategy in capacity, portfolio, and geographic expansion.

Approximately KRW 2.71 trillion of the offering proceeds are earmarked for the acquisition of PolyPeptide Group, a significant stride towards broadening the company's portfolio into peptide-based therapeutics. The remaining KRW 290 billion will be allocated to the expansion of Bio Campus II, a strategic move to enhance the company's manufacturing capabilities.

John Rim, President and CEO of Samsung Biologics, expressed confidence in their ability to execute this three-pronged growth strategy, positioning the company for a stronger leadership role and enduring shareholder value. The rights offering involves the issuance of approximately 2,270,000 new common shares at a price of KRW 1,322,000 each, which is around 15% lower than the reference price.

The total funds raised are estimated to account for roughly 4.90% of the company's current market capitalization. Subscribers include existing shareholders on a pro-rata basis, with any unsubscribed shares subject to a general public offering. Of the new shares, 20% will be designated for Samsung Biologics' employee stock ownership plan, with the rest offered to shareholders proportionally.